Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. (4th October 2018)

• Record Type: Journal Article
• Authors: Boyle, Frances; Beith, Jane; Burslem, Katie; de Boer, Richard; Hui, Rina; Lim, Elgene; McCarthy, Nicole; Redfern, Andrew; Woodward, Natasha
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 14(2018)Supplement 4
• Page Start: 3
• Page End: 11
• Publication Date: 2018-10-04
• Subjects: CDK4/6 inhibitor -- endocrine therapy -- metastatic breast cancer; Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.13064
• Languages: English
• ISSNs: 1743-7555

Abstract

Abstract: Resistance to endocrine therapy is a significant therapeutic challenge in the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) advanced breast cancer. Cyclin‐dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy have been shown to improve progression free survival, overall response rate and clinical benefit rate in women with HR+ HER2– metastatic breast cancer compared with endocrine therapy alone. This review examines the clinical evidence to support the use of CDK4/6 inhibitors in first and second line settings. Practical guidance is provided for the use of CDK4/6 inhibitors, including tolerability data, monitoring requirements and management of key toxicities for each of the available agents.